Insmed Statistics
Total Valuation
Insmed has a market cap or net worth of $3.68 billion. The enterprise value is $4.26 billion.
| Market Cap | 3.68B |
| Enterprise Value | 4.26B |
Important Dates
The next estimated earnings date is Thursday, May 2, 2024, before market open.
| Earnings Date | May 2, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Insmed has 148.49 million shares outstanding. The number of shares has increased by 14.14% in one year.
| Shares Outstanding | 148.49M |
| Shares Change (YoY) | +14.14% |
| Shares Change (QoQ) | +1.37% |
| Owned by Insiders (%) | 1.09% |
| Owned by Institutions (%) | 103.14% |
| Float | 147.09M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 12.07 |
| Forward PS | 10.17 |
| PB Ratio | n/a |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 13.96 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.12
| Current Ratio | 4.12 |
| Quick Ratio | 3.64 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -8.14 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -53.40% |
| Return on Capital (ROIC) | -69.09% |
| Revenue Per Employee | $334,658 |
| Profits Per Employee | -$821,894 |
| Employee Count | 912 |
| Asset Turnover | 0.22 |
| Inventory Turnover | 0.86 |
Taxes
In the past 12 months, Insmed has paid $2.56 million in taxes.
| Income Tax | 2.56M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +40.67% in the last 52 weeks. The beta is 0.92, so Insmed's price volatility has been similar to the market average.
| Beta (1Y) | 0.92 |
| 52-Week Price Change | +40.67% |
| 50-Day Moving Average | 27.47 |
| 200-Day Moving Average | 25.70 |
| Relative Strength Index (RSI) | 33.36 |
| Average Volume (30 Days) | 1,636,133 |
Short Selling Information
The latest short interest is 9.04 million, so 6.09% of the outstanding shares have been sold short.
| Short Interest | 9.04M |
| Short Previous Month | 8.84M |
| Short % of Shares Out | 6.09% |
| Short % of Float | 6.15% |
| Short Ratio (days to cover) | 6.31 |
Income Statement
In the last 12 months, Insmed had revenue of $305.21 million and -$749.57 million in losses. Loss per share was -$5.34.
| Revenue | 305.21M |
| Gross Profit | 239.64M |
| Operating Income | -709.63M |
| Pretax Income | -747.01M |
| Net Income | -749.57M |
| EBITDA | -645.53M |
| EBIT | -665.32M |
| Loss Per Share | -$5.34 |
Balance Sheet
The company has $780.45 million in cash and $1.36 billion in debt, giving a net cash position of -$578.58 million or -$3.90 per share.
| Cash & Cash Equivalents | 780.45M |
| Total Debt | 1.36B |
| Net Cash | -578.58M |
| Net Cash Per Share | -$3.90 |
| Equity / Book Value | -331.92M |
| Book Value Per Share | -2.24 |
| Working Capital | 703.43M |
Cash Flow
In the last 12 months, operating cash flow was -$536.25 million and capital expenditures -$13.29 million, giving a free cash flow of -$549.54 million.
| Operating Cash Flow | -536.25M |
| Capital Expenditures | -13.29M |
| Free Cash Flow | -549.54M |
| FCF Per Share | -$3.91 |
Margins
Gross margin is 78.52%, with operating and profit margins of -232.51% and -245.59%.
| Gross Margin | 78.52% |
| Operating Margin | -232.51% |
| Pretax Margin | -244.76% |
| Profit Margin | -245.59% |
| EBITDA Margin | -211.51% |
| EBIT Margin | -217.99% |
| FCF Margin | -180.05% |
Dividends & Yields
Insmed does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -14.14% |
| Shareholder Yield | -14.14% |
| Earnings Yield | -20.35% |
| FCF Yield | -14.92% |
Analyst Forecast
The average price target for Insmed is $45.36, which is 82.90% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $45.36 |
| Price Target Difference | 82.90% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 11 |
| Revenue Growth Forecast (5Y) | 41.51% |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on March 3, 2011. It was a reverse split with a ratio of 1:10.
| Last Split Date | Mar 3, 2011 |
| Split Type | Reverse |
| Split Ratio | 1:10 |
Scores
Insmed has an Altman Z-Score of -3.09 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -3.09 |
| Piotroski F-Score | 3 |